<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146610</url>
  </required_header>
  <id_info>
    <org_study_id>DP303c201801</org_study_id>
    <nct_id>NCT04146610</nct_id>
  </id_info>
  <brief_title>Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors</brief_title>
  <official_title>A Phase Ia, Multicenter, Open and Dose-increasing Study of DP303c to Evaluate the Safety , Pharmacokinetics, Immunogenicity and Antitumor Activity of Subjects With HER2-Positive Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase Ia, multicenter, open and dose-increasing study of DP303c to evaluate the safety ,&#xD;
      pharmacokinetics, immunogenicity and antitumor activity of subjects with HER2-positive&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose escalation study: Primary purpose: To investigate the safety and tolerability of DP303c&#xD;
      in subjects with HER2-positive advanced solid tumors . Secondary purpose:1. To characterize&#xD;
      the pharmacokinetics(PK) profile of DP303c;2. To assess the preliminary anti tumor activity&#xD;
      of DP303c; 3. To characterize immunogenicity of DP303c.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Tolerance Dose (MTD) of Dp303c</measure>
    <time_frame>The first treatment cycle 21 days</time_frame>
    <description>The dose level in which &gt;= 2 out of 6 patients have dose-limiting toxicity (DLT). The MTD is defined as the previous dose level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of DP303c</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>The pharmacokinetics(PK) profile of DP303c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of peak plasma concentration (Tmax)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>The pharmacokinetics(PK) profile of DP303c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) of DP303c</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>The pharmacokinetics(PK) profile of DP303c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>To preliminarily evaluate ORR in patients with advanced solid tumors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>To preliminarily evaluate DoR in patients with advanced solid tumors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity (anti-drug antibody ADA)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Percentage of subjects producing detectable anti-drug antibodies (ADA)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dp303c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose grouping</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>an antibody drug conjugate</intervention_name>
    <description>Multiple dose grouping</description>
    <arm_group_label>Dp303c</arm_group_label>
    <other_name>ADC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntary agreement to provide written informed consent；&#xD;
&#xD;
          -  Aged 18 to 75 years, both male and female;&#xD;
&#xD;
          -  Patients with advanced solid tumors diagnosed by histology and / or cytology,&#xD;
             confirmed to be HER2 positive by pathological examination, unable to accept or have no&#xD;
             standard treatment, failure of standard treatment (disease progress or treatment&#xD;
             without remission after treatment) or intolerable patients; HER2-positive is defined&#xD;
             as IHC 2+ and ISH positive or IHC 3+； IHC scores of breast cancer and gastric cancer&#xD;
             are based on their respective standards, while IHC scores of other cancers are based&#xD;
             on the scoring standards of breast cancer；&#xD;
&#xD;
          -  The ECOG performance status is 0 to 1,and the expected survival time is more than 3&#xD;
             months；&#xD;
&#xD;
          -  Subjects must have laboratory values within the limits described below:&#xD;
&#xD;
        ANC ≥1.5 x 109/L Platelet count ≥100 x 109/L Hemoglobin ≥9 g/dL Serum creatinine within&#xD;
        normal limits OR creatinine clearance ≥60 mL/minute Serum total bilirubin ≤1.5 x ULN (up to&#xD;
        3 x ULN in subjects with Gilbert's syndrome) AST (SGOT) and ALT (SGPT) ≤2.5 x ULN (OR ≤5 X&#xD;
        ULN for subjects with liver metastases) PT/INR and APTT ≤1.5 x ULN&#xD;
&#xD;
          -  According to the RECIST v1.1 standard, there must be a measurable lesion at the base&#xD;
             line；&#xD;
&#xD;
          -  WOCBP must have a negative pregnancy test prior to study entry；&#xD;
&#xD;
          -  WOCBP and male subjects must agree to use adequate contraception from study entry&#xD;
             through at least 12 weeks after the last dose of study drug (see Appendix 5)；&#xD;
&#xD;
          -  A washout period is required for subjects who have recently received systemic&#xD;
             antitumor therapy. The period prior to the subject's planned first dose of DP303c must&#xD;
             be either at least 28 days or 5 half-lives, whichever is shorter. Antitumor therapy&#xD;
             includes chemotherapy, immunotherapy, targeted therapy, endocrine therapy,&#xD;
             radiotherapy (except local radiotherapy for pain relief, 14 days after treatment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women；&#xD;
&#xD;
          -  Refusal to use effective methods of contraception (see inclusion criteria for&#xD;
             details)；&#xD;
&#xD;
          -  Not recovered from AEs caused by previous drugs or radiotherapy (reference NCI CTCAE&#xD;
             5.0, ≤Grade 1 or at baseline), with the exception of alopecia；&#xD;
&#xD;
          -  History of cardiac dysfunction with LVEF &lt;40% while on trastuzumab therapy；&#xD;
&#xD;
          -  Subjects with a history of allergy to any components(tratozumab analogues, MMAE,&#xD;
             sodium citrate dihydrate, citrate monohydrate, polysorbitol 20 and sucrose, etc.) of&#xD;
             DP303cand those who researchers consider to be more serious；&#xD;
&#xD;
          -  A history of central nervous system (CNS) metastases or epilepsy, asymptomatic or&#xD;
             stable, and not requiring treatment at least 4 weeks before study therapy began；&#xD;
&#xD;
          -  Active lung infection or pneumonitis or a history of non-infectious interstitial lung&#xD;
             disease；&#xD;
&#xD;
          -  Requires supplemental oxygen；&#xD;
&#xD;
          -  History of congestive heart failure, unstable angina pectoris, unstable atrial&#xD;
             fibrillation, or cardiac arrhythmia. Subjects who have the following types of cardiac&#xD;
             impairment at the time of enrollment:&#xD;
&#xD;
        New York Heart Association class III or IV heart disease Uncontrolled angina, congestive&#xD;
        heart failure, or myocardial infarction within 6 months prior to enrolment An LVEF by&#xD;
        echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan &lt;50% or below the lower limit&#xD;
        of normal for the institution QT interval prolongation (&gt;450 ms in males, &gt;470 ms in&#xD;
        females),QT interval correction (QTcF) was corrected by Fridericia formula&#xD;
&#xD;
          -  In the first 90 daysof the study, Cumulative anthracycline dose ≥360 mg/m2 doxorubicin&#xD;
             or equivalent；&#xD;
&#xD;
          -  Peripheral neuropathy ≥Grade 2 or greater (NCI CTCAE v 5.0)；&#xD;
&#xD;
          -  12.Non-manageable electrolyte imbalances including hypokalemia, hypocalcemia, or&#xD;
             hypomagnesemia (≥Grade 2 or greater based on NCI CTCAE v 5.0)；&#xD;
&#xD;
          -  Any uncontrollable intercurrent illness, infection, or other conditions that could&#xD;
             limit study compliance or interfere with assessments；&#xD;
&#xD;
          -  Serologic status reflecting active hepatitis B or C infection；&#xD;
&#xD;
          -  Subjects with immunodeficiency, including HIV positive；&#xD;
&#xD;
          -  Patients were treated with CYP3A inhibitors within 14 days of the first dose (drugs&#xD;
             that increased specific CYP substrate AUC ≥ 5 times, such as Mibefradil, verapamil,&#xD;
             diltiazem, nefazodone, clarithromycin, Telithromycin, Troleandomycin, Erythromycin,&#xD;
             fluconazole, itraconazole, ketoconazole,&#xD;
             Posaconazole,VoriconazoleTablets，Elvitegravir，indinavir，lopinavir，&#xD;
             Nelfinavir，Ritonavir，Saquinavir， Boceprevir，Incivo，telaprevir，Conivaptan，idelalisib)&#xD;
             or strong CYP3A inducers (Avasimibe, phenobarbital, phenytoin,&#xD;
             carbamazepine,Rifampicin, rifabutin,enzalutamide, mitotane, Hypericum perforatum )；&#xD;
&#xD;
          -  Other serious or uncontrollable diseases or conditions that may affect the assessment&#xD;
             of the primary endpoint or that the investigator considers to be at risk for&#xD;
             participants participating in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

